Verrica Pharmaceuticals Inc. (VRCA)
NASDAQ: VRCA · Real-Time Price · USD
4.150
-0.080 (-1.89%)
Oct 17, 2025, 4:00 PM EDT - Market closed
Verrica Pharmaceuticals Employees
Verrica Pharmaceuticals had 71 employees as of December 31, 2024. The number of employees decreased by 29 or -29.00% compared to the previous year.
Employees
71
Change (1Y)
-29
Growth (1Y)
-29.00%
Revenue / Employee
$207,099
Profits / Employee
-$684,507
Market Cap
39.20M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 71 | -29 | -29.00% |
| Dec 31, 2023 | 100 | 78 | 354.55% |
| Dec 31, 2022 | 22 | -16 | -42.11% |
| Dec 31, 2021 | 38 | 9 | 31.03% |
| Dec 31, 2020 | 29 | 12 | 70.59% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
VRCA News
- 11 days ago - Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting - GlobeNewsWire
- 4 weeks ago - Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum - GlobeNewsWire
- 6 weeks ago - Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - Verrica Pharmaceuticals Inc. (VRCA) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025 - GlobeNewsWire
- 3 months ago - Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025 - GlobeNewsWire
- 3 months ago - Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts - GlobeNewsWire